The Gladstone Center for Translational Research facilitates interactions between Gladstone scientists and the biomedical industry—including venture capitalists, biotech firms and large corporations. The Center’s primary goal is to translate the results of Gladstone’s basic science into therapeutics that help patients with cardiovascular, viral or neurological diseases. Working in concert with our intellectual property department, the Center engages with companies interested in licensing our patented technology, collaborating on research goals or launching startups. For example, this molecule-to-marketplace business unit facilitates technology transfer through collaborations with partners such as Lundbeck, Bristol-Myers Squibb and Takeda. If you’d like to explore opportunities to partner with Gladstone, please get in touch with Stephen Freedman, PhD, our Vice President for Corporate Liaison and Ventures.
Stephen Freedman, PhD
Vice President for Corporate Liaison and Ventures
|Joan Bruland, JD
Vice President for Intellectual Property and Legal Affairs